Clinical implications of mismatch repair deficiency in prostate cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Siegel RL , Miller KD , Jemal A . Cancer statistics, 2017. CA Cancer J. Clin. 67(1), 7–30 (2017).
  MedlineGoogle Scholar
• 2. Walsh PC , DeWeese TL , Eisenberger MA . Clinical practice. Localized prostate cancer. N. Engl. J. Med. 357(26), 2696–2705 (2007).
  Medline CASGoogle Scholar
• 3. Pritchard CC , Offit K , Nelson PS . DNA-repair gene mutations in metastatic prostate cancer. N. Engl. J. Med. 375(18), 1804–1805 (2016).
  MedlineGoogle Scholar
• 4. Hanahan D , Weinberg RA . Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011).
  Medline CASGoogle Scholar
• 5. Boland CR , Goel A . Microsatellite instability in colorectal cancer. Gastroenterology 138(6), 2073–2087.e2073 (2010).
  Medline CASGoogle Scholar
• 6. Mackay J , Szecsei CM . Genetic counselling for hereditary predisposition to ovarian and breast cancer. Ann. Oncol. 21(Suppl. 7), vii334–vii338 (2010).
  MedlineGoogle Scholar
• 7. Brown JS , O'Carrigan B , Jackson SP , Yap TA . Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov. 7(1), 20–37 (2017).
  Medline CASGoogle Scholar
• 8. Laghi L , Bianchi P , Malesci A . Differences and evolution of the methods for the assessment of microsatellite instability. Oncogene 27(49), 6313–6321 (2008).
  Medline CASGoogle Scholar
• 9. Le DT , Durham JN , Smith KN et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349), 409–413 (2017). •• With objective response rates in 53% of patients, this study highlighted the efficacy of PD-1 blockade in patients with advanced mismatch repair-deficient cancers.
  Medline CASGoogle Scholar
• 10. Diaz LA , Le DT . PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 373(20), 1979 (2015).
  MedlineGoogle Scholar
• 11. Le DT , Uram JN , Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372(26), 2509–2520 (2015).
  Medline CASGoogle Scholar
• 12. US FDA. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. (2017). www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm
  Google Scholar
• 13. Robinson D , Van Allen EM , Wu YM et al. Integrative clinical genomics of advanced prostate cancer. Cell 162(2), 454 (2015).
  Medline CASGoogle Scholar
• 14. Schweizer MT , Cheng HH , Tretiakova MS et al. Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Oncotarget 7(50), 82504–82510 (2016).
  MedlineGoogle Scholar
• 15. Hoeijmakers JH . Genome maintenance mechanisms for preventing cancer. Nature 411(6835), 366–374 (2001).
  Medline CASGoogle Scholar
• 16. Lynch HT , Snyder CL , Shaw TG , Heinen CD , Hitchins MP . Milestones of Lynch syndrome: 1895–2015. Nat. Rev. Cancer 15(3), 181–194 (2015).
  Medline CASGoogle Scholar
• 17. Leach FS , Nicolaides NC , Papadopoulos N et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75(6), 1215–1225 (1993).
  Medline CASGoogle Scholar
• 18. Lynch HT , de la Chapelle A . Hereditary colorectal cancer. N. Engl. J. Med. 348(10), 919–932 (2003).
  Medline CASGoogle Scholar
• 19. Palomaki GE , McClain MR , Melillo S , Hampel HL , Thibodeau SN . EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet. Med. 11(1), 42–65 (2009).
  MedlineGoogle Scholar
• 20. Strand M , Prolla TA , Liskay RM , Petes TD . Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair. Nature 365(6443), 274–276 (1993).
  Medline CASGoogle Scholar
• 21. Peltomäki P , Lothe RA , Aaltonen LA et al. Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res. 53(24), 5853–5855 (1993).
  Medline CASGoogle Scholar
• 22. Lawes DA , SenGupta S , Boulos PB . The clinical importance and prognostic implications of microsatellite instability in sporadic cancer. Eur. J. Surg. Oncol. 29(3), 201–212 (2003).
  Medline CASGoogle Scholar
• 23. Bauer CM , Ray AM , Halstead-Nussloch BA et al. Hereditary prostate cancer as a feature of Lynch syndrome. Fam. Cancer 10(1), 37–42 (2011).
  MedlineGoogle Scholar
• 24. Raymond VM , Mukherjee B , Wang F et al. Elevated risk of prostate cancer among men with Lynch syndrome. J. Clin. Oncol. 31(14), 1713–1718 (2013).
  MedlineGoogle Scholar
• 25. Bratt O . What should a urologist know about hereditary predisposition to prostate cancer? BJU Int. 99(4), 743–747 discussion 747–748 (2007).
  MedlineGoogle Scholar
• 26. Win AK , Lindor NM , Young JP et al. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J. Natl Cancer Inst. 104(18), 1363–1372 (2012).
  Medline CASGoogle Scholar
• 27. Pritchard CC , Morrissey C , Kumar A et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat. Commun. 5, 4988 (2014). • Identified parallels and differences in mechanisms of hypermutation in prostate cancer compared with other microsatellite instability-associated cancers.
  Medline CASGoogle Scholar
• 28. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163(4), 1011–1025 (2015).
  MedlineGoogle Scholar
• 29. Win AK , Young JP , Lindor NM et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J. Clin. Oncol. 30(9), 958–964 (2012).
  Medline CASGoogle Scholar
• 30. Haraldsdottir S , Hampel H , Wei L et al. Prostate cancer incidence in males with Lynch syndrome. Genet. Med. 16(7), 553–557 (2014).
  MedlineGoogle Scholar
• 31. Grindedal EM , Møller P , Eeles R et al. Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol. Biomarkers Prev. 18(9), 2460–2467 (2009).
  Medline CASGoogle Scholar
• 32. Chen Y , Wang J , Fraig MM et al. Defects of DNA mismatch repair in human prostate cancer. Cancer Res. 61(10), 4112–4121 (2001).
  Medline CASGoogle Scholar
• 33. Egawa S , Uchida T , Suyama K et al. Genomic instability of microsatellite repeats in prostate cancer: relationship to clinicopathological variables. Cancer Res. 55(11), 2418–2421 (1995).
  Medline CASGoogle Scholar
• 34. Uchida T , Wada C , Wang C et al. Microsatellite instability in prostate cancer. Oncogene 10(5), 1019–1022 (1995).
  Medline CASGoogle Scholar
• 35. Antonarakis ES , Shaukat F , Isaacsson Velho P et al. Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur. Urol. 75(3), 378–382 (2019). •• Complement to the Abida paper, highlights outcomes of men with advanced prostate cancer and DNA mismatch repair mutations.
  Medline CASGoogle Scholar
• 36. Isaacsson Velho P , Silberstein JL , Markowski MC et al. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. Prostate 78(5), 401–407 (2018).
  MedlineGoogle Scholar
• 37. Pritchard CC , Mateo J , Walsh MF et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375(5), 443–453 (2016). •• This multicenter study highlighted the incidence of germline mutations in genes mediating DNA-repair processes in men with metastatic prostate cancer, as compared with localized prostate cancer.
  Medline CASGoogle Scholar
• 38. Robinson D , Van Allen EM , Wu YM et al. Integrative clinical genomics of advanced prostate cancer. Cell 161(5), 1215–1228 (2015).
  Medline CASGoogle Scholar
• 39. Guedes LB , Antonarakis ES , Schweizer MT et al. MSH2 loss in primary prostate cancer. Clin. Cancer Res. 23(22), 6863–6874 (2017).
  Medline CASGoogle Scholar
• 40. Shenderov EIP , Velho PI , Awan A et al. Genomic characterization of pulmonary-metastatic prostate cancer: a unique molecular subtype. J. Clin. Oncol. 37, 210–211 (2019).
  Google Scholar
• 41. Nicolosi P , Ledet E , Yang S et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol. 5(4), 523–528 (2019).
  Google Scholar
• 42. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Prostate Cancer. Version 2.2018. www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
  Google Scholar
• 43. Mygatt JG , Osborn DJ . DNA-repair gene mutations in metastatic prostate cancer. N. Engl. J. Med. 375(18), 1803–1804 (2016).
  MedlineGoogle Scholar
• 44. Azzouzi AR , Catto JW , Rehman I et al. Clinically localised prostate cancer is microsatellite stable. BJU Int. 99(5), 1031–1035 (2007).
  Medline CASGoogle Scholar
• 45. Rodrigues DN , Rescigno P , Liu D et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J. Clin. Invest. 128(11), 5185 (2018).
  MedlineGoogle Scholar
• 46. Fraser M , Sabelnykova VY , Yamaguchi TN et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature 541(7637), 359–364 (2017).
  Medline CASGoogle Scholar
• 47. Armenia J , Wankowicz SAM , Liu D et al. The long tail of oncogenic drivers in prostate cancer. Nat. Genet. 50(5), 645–651 (2018).
  Medline CASGoogle Scholar
• 48. Gao X , Wu N , Grignon D et al. High frequency of mutator phenotype in human prostatic adenocarcinoma. Oncogene 9(10), 2999–3003 (1994).
  Medline CASGoogle Scholar
• 49. Antonarakis ES . A new molecular taxonomy to predict immune checkpoint inhibitor sensitivity in prostate cancer. Oncologist 24(4), 430–432 (2019). • Highlights advances in our understanding of PD-1 inhibition in prostate cancer.
  MedlineGoogle Scholar
• 50. Goodfellow PJ , Billingsley CC , Lankes HA et al. Combined microsatellite instability, MLH1 methylation analysis, and immunohistochemistry for lynch syndrome screening in endometrial cancers from GOG210: an NRG Oncology and Gynecologic Oncology Group Study. J. Clin. Oncol. 33(36), 4301–4308 (2015).
  MedlineGoogle Scholar
• 51. Hause RJ , Pritchard CC , Shendure J , Salipante SJ . Classification and characterization of microsatellite instability across 18 cancer types. Nat. Med. 22(11), 1342–1350 (2016).
  Medline CASGoogle Scholar
• 52. Bacher JW , Flanagan LA , Smalley RL et al. Development of a fluorescent multiplex assay for detection of MSI-High tumors. Dis. Markers 20(4–5), 237–250 (2004).
  MedlineGoogle Scholar
• 53. Palmieri G , Colombino M , Cossu A , Marchetti A , Botti G , Ascierto PA . Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy? J. Transl. Med. 15(1), 17 (2017).
  MedlineGoogle Scholar
• 54. Hempelmann JA , Scroggins SM , Pritchard CC , Salipante SJ . MSI plus for integrated colorectal cancer molecular testing by next-generation sequencing. J. Mol. Diagn. 17(6), 705–714 (2015).
  Medline CASGoogle Scholar
• 55. Teply BA , Antonarakis ES . Treatment strategies for DNA repair-deficient prostate cancer. Expert Rev. Clin. Pharmacol. 10(8), 889–898 (2017).
  Medline CASGoogle Scholar
• 56. Pritchard CC , Morrissey C , Kumar A et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat. Commun. 5, 1–6 (2014). • MSI-H prostate cancer relatively common in this dataset, with description of unique comp rearrangements as underlying mechanism.
  Google Scholar
• 57. Kelderman S , Schumacher TN , Kvistborg P . Mismatch repair-deficient cancers are targets for anti-PD-1 therapy. Cancer Cell 28(1), 11–13 (2015).
  Medline CASGoogle Scholar
• 58. Abida W , Cheng ML , Armenia J et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA 5(4), 471–478 (2019). •• Largest study to date evaluating the prevalence of microsatellite instability in prostate cancer and its association with response to immune checkpoint blockade.
  Google Scholar
• 59. Mayrhofer M , De Laere B , Whitington T et al. Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Med. 10(1), 85 (2018).
  Medline CASGoogle Scholar
• 60. Abida W , Gopalan A , Armenia J et al. Identifying mismatch repair-deficient prostate cancer for immune checkpoint therapy. J. Clin. Oncol. 36(15 Suppl.), 5020–5021 (2018).
  Google Scholar
• 61. Alexandrov LB , Nik-Zainal S , Wedge DC et al. Signatures of mutational processes in human cancer. Nature 500(7463), 415–421 (2013).
  Medline CASGoogle Scholar
• 62. Haffner MC , Guner G , Taheri D et al. Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer. Am. J. Pathol. 188(6), 1478–1485 (2018).
  Medline CASGoogle Scholar
• 63. Fankhauser CD , Schüffler PJ , Gillessen S et al. Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget 9(12), 10284–10293 (2018).
  MedlineGoogle Scholar
• 64. Kantoff PW , Higano CS , Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411–422 (2010).
  Medline CASGoogle Scholar
• 65. Rexer H , Graefen M , Merseburger A . [Phase II study of pembrolizumab (MK-3475) in patients with metastatic castration-resistant prostate cancer (KEYNOTE-199)-study AP 93/16 of the AUO]. Urologe A 56(11), 1471–1472 (2017).
  Medline CASGoogle Scholar
• 66. Attalla K , Sfakianos JP , Galsky MD . Current role of checkpoint inhibitors in urologic cancers. Cancer Treat Res. 175, 241–258 (2018).
  MedlineGoogle Scholar
• 67. De Bono JS , Goh JC , Ojamaa K et al. KEYNOTE-199: pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer. J. Clin. Oncol. 36(15), 5007–5008 (2018).
  Google Scholar
• 68. Hansen AR , Massard C , Ott PA et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann. Oncol. 29(8), 1807–1813 (2018).
  Medline CASGoogle Scholar
• 69. Kwon ED , Drake CG , Scher HI et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, Phase III trial. Lancet Oncol. 15(7), 700–712 (2014).
  Medline CASGoogle Scholar
• 70. Beer TM , Kwon ED , Drake CG et al. Randomized, double-blind, Phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J. Clin. Oncol. 35(1), 40–47 (2017).
  Medline CASGoogle Scholar
• 71. Topalian SL , Hodi FS , Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012).
  Medline CASGoogle Scholar
• 72. Smits M , Westdorp H , Gorris M et al. Correlates of response to anti-PD-1 immune checkpoint blockade in mismatch repair proficient and deficient patients with metastatic castration resistant prostate cancer. ASCO Meeting Abstracts 5036, (2018).
  Google Scholar
• 73. Vogelstein B , Papadopoulos N , Velculescu VE , Zhou S , Diaz LA , Kinzler KW . Cancer genome landscapes. Science 339(6127), 1546–1558 (2013).
  Medline CASGoogle Scholar
• 74. Rizvi NA , Hellmann MD , Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230), 124–128 (2015).
  Medline CASGoogle Scholar
• 75. Miao D , Margolis CA , Vokes NI et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat. Genet. 50(9), 1271–1281 (2018).
  Medline CASGoogle Scholar
• 76. Millis SZ , Ikeda S , Reddy S , Gatalica Z , Kurzrock R . Landscape of phosphatidylinositol-3-kinase pathway alterations across 19 784 diverse solid tumors. JAMA Oncol. 2(12), 1565–1573 (2016).
  MedlineGoogle Scholar
• 77. Grosso JF , Goldberg MV , Getnet D et al. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J. Immunol. 182(11), 6659–6669 (2009).
  Medline CASGoogle Scholar
• 78. Woo SR , Turnis ME , Goldberg MV et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72(4), 917–927 (2012).
  Medline CASGoogle Scholar
• 79. Shin DS , Zaretsky JM , Escuin-Ordinas H et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7(2), 188–201 (2017).
  Medline CASGoogle Scholar
• 80. Klempner SS , Schrock A , Ali S et al. Acquired CTNNB1 mutation drives immune checkpoint inhibitor-acquired resistance in a microsatellite instability-high gastroesophageal adenocarcinoma with brain metastases. JCO Precis. Oncol. 1–8 (2019).
  Google Scholar
• 81. Zhan T , Rindtorff N , Boutros M . Wnt signaling in cancer. Oncogene 36, 1461–1473 (2017).
  Medline CASGoogle Scholar
• 82. Dierssen JW , de Miranda NF , Ferrone S et al. HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. BMC Cancer 7, 33 (2007).
  MedlineGoogle Scholar
• 83. Zaretsky JM , Garcia-Diaz A , Shin DS et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375(9), 819–829 (2016).
  Medline CASGoogle Scholar
• 84. Sade-Feldman M , Jiao YJ , Chen JH et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8(1), 1136 (2017).
  MedlineGoogle Scholar
• 85. Wang X , Schoenhals JE , Li A et al. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res. 77(4), 839–850 (2017).
  Medline CASGoogle Scholar
• 86. Thomas DA , Massagué J . TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8(5), 369–380 (2005).
  Medline CASGoogle Scholar
• 87. Baas M , Besançon A , Goncalves T et al. TGFβ-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance. Elife 5, e08133 (2016). • Found that five marker microsatellite instability-PCR panel had inferior sensitivity when applied to prostate cancer and that next-generation sequencing testing with expanded panel of markers performs well.
  MedlineGoogle Scholar
• 88. Kaur HB , Guedes LB , Lu J et al. Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer. Mod. Pathol. 31(10), 1539–1552 (2018).
  Medline CASGoogle Scholar
• 89. Cheng F , Eng C . PTEN mutations trigger resistance to immunotherapy. Trends Mol. Med. 25(6), 461–463 (2019).
  Medline CASGoogle Scholar
• 90. Massari F , Ciccarese C , Caliò A et al. Magnitude of PD-1, PD-L1 and T lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: an exploratory analysis. Target Oncol. 11(3), 345–351 (2016).
  MedlineGoogle Scholar
• 91. Gevensleben H , Dietrich D , Golletz C et al. The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer. Clin. Cancer Res. 22(8), 1969–1977 (2016).
  Medline CASGoogle Scholar
• 92. Bishop JL , Sio A , Angeles A et al. PD-L1 is highly expressed in enzalutamide resistant prostate cancer. Oncotarget 6(1), 234–242 (2015).
  MedlineGoogle Scholar
• 93. Wu YM , Cieślik M , Lonigro RJ et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell 173(7), 1770–1782.e1714 (2018).
  Medline CASGoogle Scholar
• 94. Antonarakis ES . Cyclin-dependent kinase 12, immunity, and prostate cancer. N. Engl. J. Med. 379(11), 1087–1089 (2018).
  MedlineGoogle Scholar
• 95. Campbell BB , Light N , Fabrizio D et al. Comprehensive analysis of hypermutation in human cancer. Cell 171(5), 1042–1056.e1010 (2017).
  Medline CASGoogle Scholar
• 96. Lee L , Ali S , Genega E et al. Aggressive-variant microsatellite-stable POLE mutant prostate cancer with high mutation burden and durable response to immune checkpoint inhibitor therapy. JCO Precis. Oncol. 1–10 (2018).
  MedlineGoogle Scholar
• 97. Kataoka K , Shiraishi Y , Takeda Y et al. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature 534(7607), 402–406 (2016).
  Medline CASGoogle Scholar
• 98. Boudadi K , Suzman DL , Anagnostou V et al. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget 9(47), 28561–28571 (2018).
  MedlineGoogle Scholar